Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BEAM 
Beam Therapeutics Inc (BEAM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BEAM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $44.07
Year Target Price $44.07
| 10 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.28% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.69B USD | Price to earnings Ratio - | 1Y Target Price 44.07 |
Price to earnings Ratio - | 1Y Target Price 44.07 | ||
Volume (30-day avg) 17 | Beta 2.08 | 52 Weeks Range 13.53 - 35.25 | Updated Date 06/29/2025 |
52 Weeks Range 13.53 - 35.25 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1596.87% |
Management Effectiveness
Return on Assets (TTM) -19.05% | Return on Equity (TTM) -38.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 626530608 | Price to Sales(TTM) 26.57 |
Enterprise Value 626530608 | Price to Sales(TTM) 26.57 | ||
Enterprise Value to Revenue 9.85 | Enterprise Value to EBITDA -7.03 | Shares Outstanding 100557000 | Shares Floating 86266522 |
Shares Outstanding 100557000 | Shares Floating 86266522 | ||
Percent Insiders 1.22 | Percent Institutions 98.07 |
Analyst Ratings
Rating 4 | Target Price 44.07 | Buy 4 | Strong Buy 10 |
Buy 4 | Strong Buy 10 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Beam Therapeutics Inc
Company Overview
History and Background
Beam Therapeutics was founded in 2017 and is pioneering precision genetic medicines through base editing. It is focused on developing therapies for serious diseases.
Core Business Areas
- Base Editing Therapeutics: Development of novel therapeutics using base editing technology for various diseases.
- Research and Development: Research and development of new base editing technologies and applications.
Leadership and Structure
John Evans (CEO), Giuseppe Ciaramelli (CFO). The company operates with a focus on research and development, with teams dedicated to specific therapeutic areas.
Top Products and Market Share
Key Offerings
- BEAM-101: BEAM-101 is Beam's lead program is for the treatment of sickle cell disease. Competitors include CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals (VRTX), and Editas Medicine (EDIT). Data is still early so no market share yet.
- BEAM-201: BEAM-201 is targeting relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL). Competitors include Novartis (NVS) and Gilead (GILD). Data is still early so no market share yet.
- BEAM-301: BEAM-301 is for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Competitors include Arrowhead Pharmaceuticals (ARWR). Data is still early so no market share yet.
Market Dynamics
Industry Overview
The gene editing industry is rapidly evolving, with significant potential for treating a wide range of diseases. Competition is intense, with numerous companies pursuing different gene editing technologies.
Positioning
Beam Therapeutics is a leader in base editing, a more precise form of gene editing compared to CRISPR-Cas9. Its competitive advantage lies in the precision and potential safety benefits of its technology.
Total Addressable Market (TAM)
The total addressable market is difficult to definitively quantify but it is estimated to be in the tens of billions of dollars, across various disease indications. Beam is well-positioned to capture a significant portion of this market, depending on the success of their clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary base editing technology
- Strong intellectual property portfolio
- Experienced management team
- Potential for highly specific and safe gene editing therapies
Weaknesses
- Early stage clinical development
- High research and development costs
- Dependence on regulatory approvals
- Competition from other gene editing companies
Opportunities
- Expanding base editing applications to new diseases
- Strategic partnerships with pharmaceutical companies
- Positive clinical trial results
- Increasing investment in gene editing technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Ethical concerns surrounding gene editing
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- ARWR
- VRTX
Competitive Landscape
Beam has advantages in base editing technology. It competes with others with CRISPR or siRNA technology. Vertex has approved products so they have a revenue advantage.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by advancing its pipeline of base editing therapies.
Future Projections: Future growth is heavily dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates suggest significant revenue potential if key programs are successful.
Recent Initiatives: Recent initiatives include advancing BEAM-101, BEAM-201, and BEAM-301 through clinical trials, expanding its pipeline, and forming strategic partnerships.
Summary
Beam Therapeutics is an innovative company in the gene editing space with a promising technology. However, it is still in the early stages of clinical development and faces significant risks. Successful clinical trial results and regulatory approvals are crucial for its future success. Beam Therapeutics needs to demonstrate clinical efficacy and safety to differentiate themselves in a crowded marketplace.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Company press releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beam Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-02-06 | CEO & Director Mr. John M. Evans M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 393 | Website https://beamtx.com |
Full time employees 393 | Website https://beamtx.com | ||
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.